(RTTNews) - Biopharmaceutical company UCB announced Wednesday that ZILBRYSQ (zilucoplan) is now available in the U.S. for the treatment of generalized myasthenia gravis (gMG) in adult patients who are ...
May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...
Nicholas J. Silvestri, MD, expects that the upcoming 2025 American Academy of Neurology Annual Meeting in San Diego will be an exciting event for the field of myasthenia gravis (MG), with anticipated ...
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
Data from the randomized MINT trial, presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, showed that the anti-CD19 monoclonal antibody ...
Richard J. Nowak, MD, is director of the Myasthenia Gravis Clinic, director of Clinical & Translational Neuromuscular Research (CTNR), and associate professor of neurology at Yale School of Medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results